Amdocs plunged about 40% in premarket trading to near $37.40 after its fiscal Q4 results exposed a contract dispute with T-Mobile that has escalated to mutual breach notices. Management guided fiscal 2027 revenue down 14.3-17.9% and adjusted EPS down 26-30%, far below consensus, and Oppenheimer downgraded the stock to Perform from Outperform.
Useful?